How convincing does the evidence need to be before we change practice? If we shift too early, then we risk giving patients useless or even harmful treatments, such as flecainide, hormone replacement therapy, and cox-2 inhibitors. But if we shift late then we (temporarily) deny the benefits of breakthroughs to our patients. Achieving …